Paul J. Thuluvath - Concepedia

Author

Paul J. Thuluvath

Also Known As

Adeyinka O. Laiyemo, Alexander Thompson, Carmen Stanca, Linda Chang, Michael Peluso, Noelle Njoku, P J Thuluvath, P THULUVATH, P Thuluvath, P. J. THULUVATH

492

Publications

24.5K

Citations

H-Index

186

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine Mercy Medical Center Mercy Medical Center University of Maryland, Baltimore

About

Paul J. Thuluvath is an author at Johns Hopkins University specializing in medicine, hepatology, and liver transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	105	9.9K
2	Health Sciences	11	12	2.3K
3	Education	1	1	161
4	Engineering	1	1	123
5	Nursing	1	1	17

Paul J. Thuluvath

193

Publications

20.2K

Citations

H-Index

Page 1

	Year	Citations
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, New England Journal of Medicine	2014	1.2K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection Tanayott Thaweethai, Sarah E. Jolley, Elizabeth W. Karlson, JAMA	2023	792
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson, James N. Cooper, Jacob Lalezari, Hepatology	2015	688
Liver Transplantation in the United States, 1999-2008 Paul J. Thuluvath, Mary K. Guidinger, John J. Fung, American Journal of Transplantation	2010	573
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Journal of Clinical Oncology	2014	572
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study Asma Poonawala, Satheesh Nair, Paul J. Thuluvath Hepatology Metabolic DisorderGastroenterologyCryptogenic CirrhosisAdvanced CirrhosisFatty Liver Disease	2000	564
Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation Satheesh Nair, Sumita Verma, Paul J. Thuluvath Hepatology Solid Organ TransplantationOrthotopic Liver TransplantationSurgeryGraft SurvivalChronic Kidney Disease	2002	538
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States Satheesh Nair, Sumita Verma, Paul J. Thuluvath Hepatology ObesityTransplantation SurgeryMetabolic SyndromeOrgan DonationTransplantation	2002	417

Page 1